Resumen

BLANCO DIAZ, Ana Tamara et al. Eritropoyetina recombinante humana en la insuficiencia renal crónica. Rev Cub Med Mil [online]. 2003, vol.32, n.4, pp. 0-0. ISSN 1561-3046.

A bibliographic review was made aimed at going deep into the study of the use of human recombinant erythropoietin in chronic kidney failure, leading to a reduction of the production of erythropoietin, main stimulating factor of erythropoiesis. Anemia was the final result of this insufficient hormonal production. The clinical manifestations of severe anemia hinder the full incorporation to normal life and its correction depends on frequent blood transfusions with the biological and non-biological created risks. The treatment with human recombinant erythropoietin is efficient, safe, and with benefitial effects that influence on a better quality life and on a higher survival. There are just a few adverse reactions. The most frequent is arterial hypertension. Besides having an increasing number of applications on in extrarenal diseases , Cuba has its own human recpmbinat erythropoietin under process of generalization with very good results.

Palabras clave : KIDNEY FAILURE, CHRONIC [therapy]; TERMINAL CARE ERYTHROPOIETIN, RECOMBINANT [therapeutic use]; DRUG COMPOUNDING; CUBA.